Skip to main content

Table 1 Clinical and primary tumor characteristics of the overall population at MBC diagnosis (N = 379)

From: Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

Characteristic N (%)
Caucasians 371 (99.2)
Median age at MBC diagnosis, years 61.2 (50.7–70.9)
BMI at MBC diagnosis (kg/m2), median (IQR) (N = 320) 27.0 (23.9–31.4)
BMI category at MBC diagnosis (N = 320) Underweight (BMI < 18.5 kg/m 2 ) 2 (0.6)
Normal (BMI ≥ 18.5 and BMI < 25 kg/m 2 ) 117 (36.6)
Overweight (BMI ≥ 25 and BMI < 30 kg/m 2 ) 102 (31.9)
Obese (BMI ≥ 30 kg/m 2 ) 99 (30.9)
Menopausal status at MBC diagnosis (N = 330) Postmenopausal 256 (77.6)
Premenopausal 66 (20.0)
Perimenopausal 8 (2.5)
Use of oral contraceptives (N = 236) 9 (3.8)
Use of hormone replacement therapy (N = 238) 10 (4.2)
Family history of breast cancer (N = 323) 47 (14.6)
Family history of ovarian cancer (N = 322) 5 (1.6)
Comorbidities at MBC diagnosisa (N = 379) Vascular disorders 61 (16.1)
Cardiac disorders 51 (13.5)
Endocrine disorders 50 (13.2)
Psychiatric disorders 24 (6.3)
Metabolism and nutrition disorders 22 (5.8)
ECOG performance status at MBC diagnosis (N = 374) PS 0–1 344 (92.0)
PS 2–3 30 (8.0)
Primary tumor location (N = 376) Left breast 189 (50.3)
Right breast 179 (47.6)
Both breasts 8 (2.1)
Primary tumor size (N = 301) Tumor size ≤ 2 cm 110 (36.5)
2 cm < tumor size ≤ 5 cm 148 (49.2)
Tumor size > 5 cm 43 (14.3)
Number of metastases at MBC diagnosis, median (IQR) (N = 264 b) 2.0 (1.0–3.0)
Distant metastatic sites (N = 369)a Bones 207 (56.1)
Lung 138 (37.4)
Liver 106 (28.7)
Lymph nodes 70 (19.0)
Brain 35 (9.5)
Pleural effusion 29 (7.9)
  1. aOnly those present in at least 5% of the population have been included
  2. bPatients for whom the precise number of metastases was known
  3. IQR, interquartile range (Q25-Q75); N, number of patients with known data for each variable